Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Cisplatin Plus Weekly Docetaxel as the First-line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

NCT01312311 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT01312311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01312311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Cisplatin Plus Weekly Docetaxel as the First-line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2006
Completion date
Not reported
Enrollment
51 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal cancer